Letter to Orexo shareholders from CEO Nikolaj Sørensen

Uppsala, Sweden – September 2, 2015 – Orexo AB (publ) informs that the CEO of
Orexo, Nikolaj Sørensen, today has sent a letter to all shareholders of the
company. The letter provides an update on the commercialization of Zubsolv® and
the sales progress in the U.S. market as well as a general business update. The
letter is also available on the company's home page at www.orexo.com.

For further information, please contact
Nikolaj Sørensen, President and CEO
Tel: +46 (0)18-780 88 00, E-mail: ir@orexo.com

About Orexo
Orexo is a specialty pharmaceutical company commercializing its proprietary
product Zubsolv® for treatment of opioid dependence in the US. Zubsolv is an
advanced formulation of buprenorphine and naloxone using Orexo’s unique
knowledge and expertise in sublingual drug delivery. R&D is focusing on
reformulation of known substances to new improved products that meet great unmet
medical needs by using its patented proprietary technologies. Orexo’s share is
listed on Nasdaq Stockholm Exchange Mid Cap (STO: ORX) and is available as ADRs
on OTCQX (ORXOY) in the US. Orexo’s global headquarters and R&D are based in
Uppsala, Sweden. www.orexo.com.

For information about ZUBSOLV and opioid dependence, please visit
www.zubsolv.com and www.outthemonster.com